Swiss stocks - Factors to watch on June 4
Swiss stocks - Factors to watch on June 4 ZURICH/GDANSK, June 4 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday:
PARTNERS GROUPPGHN.S
Partners Group capped withdrawals from an $8.6 billion private equity fund, fuelling concerns over risks in alternative investments.
NOVARTISNOVN.S
Novartis said Cosentyx showed superior remission rates in polymyalgia rheumatica and has filed for approval in the U.S., EU and Japan.
BURCKHARDT COMPRESSIONBCHN.S
Burckhardt Compression sees fiscal year 2026 sales between CHF 900 MLN and CHF 1000 MLN.
ANALYSTS' VIEWS
SWISS LIFE HOLDINGSLHN.S - JP MORGAN RAISES TARGET PRICE TO CHF 745 FROM CHF 735
ECONOMY
*Swiss May CPI data due at 0630 GMT. Seen at +0.3% m/m, +0.8% y/y.
*Swiss May unemployment data due at 0700 GMT. Seen at 3.0%.
(Reporting by Zurich newsroom and Gdansk newsroom)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES
Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH
All equity news E
SPEED GUIDES: EQUITY, EQUITY/NEWS1, EUR/EQUITY, SWITZERLAND, REUTERS
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'